Hims GLP-1 Review: The $49 Pill Era Ended in March 2026 — What's Left

Hims spent 2024–2025 as one of the biggest compounded-semaglutide sellers in the US. The pricing was aggressive enough to draw a public confrontation with Novo Nordisk. On February 5, 2026, Hims announced a $49 compounded semaglutide pill option. Novo Nordisk sued four days later. The case was dropped on March 9, 2026, and Hims moved its US weight-loss business to branded medication. The platform is now a branded-only storefront selling Wegovy pens and pills, Zepbound vials and KwikPens, Ozempic, and Lilly's new oral GLP-1 Foundayo — all behind a $149/month membership.

Direct answer: As of August 20, 2026, Hims sells GLP-1 medication at flat cash prices starting at $149/month (Wegovy Pill, Ozempic Pill, Foundayo Pill), $199/month (Wegovy Pen, Ozempic injection), $299/month (Zepbound Vial or KwikPen) and $1,899/month for standard branded Zepbound and Mounjaro pens. Every price is medication only. A Hims Weight Loss Membership is mandatory — $39 for month one, then $149/month — and medication cannot be bought without it. That makes the realistic all-in floor $188 in month one and $298/month after that, and the ceiling $2,048/month. Hims does not bill insurance: its own FAQ says insurance "isn't required," and there is no benefit-check or prior-authorization workflow anywhere in the weight-loss product pages. The medication fee is FSA/HSA eligible; the membership fee is not. Compounded semaglutide is no longer on the storefront — Hims' Q2 2026 10-Q says it still provides access to compounded GLP-1s "on a limited scale." Worth knowing: unlike branded Wegovy, compounded semaglutide is not an FDA-approved product and has not been reviewed by the FDA for safety, effectiveness, or quality. Care is asynchronous by default — a video or audio visit only happens where a state requires one — with no required labs and no obesity-medicine specialists. Best for tech-comfortable adults paying cash who want fast, branded GLP-1 access; less appropriate for complex medical histories or anyone whose insurance would cover the drug elsewhere.

Sponsored · Pallas Health

100% online · no office visits

Clinician-personalized compounded semaglutide, prepared in the USA.

A US-licensed clinician reviews every intake and personalizes the plan, with FDA-approved options or compounded medication prepared by US-licensed pharmacies. Prescribed only when clinically appropriate. Ships free if eligible. No membership or platform fees.

See if you are eligible

Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc. We may earn a commission.

Current Lineup (August 2026)

Prices below are what hims.com lists for medication only. Add the $149/month membership to every row.

Membership fee: $39 for month 1, auto-renews at $149/month. Hims states plainly that medication is not available without an active membership, and that cancelling the membership also cancels any active medication plan.

Note the split on tirzepatide: the same molecule is $299/month as a Zepbound vial or KwikPen and $1,899/month as standard branded Zepbound pens. Ozempic and Mounjaro carry type 2 diabetes labels, so Hims lists them as prescribed at a clinician's discretion for patients who meet eligibility criteria — using them for weight loss is off-label.

The Hims GLP-1 Pills

Four of the ten products on the storefront are tablets, which is the single biggest change to this platform since the settlement. They are not interchangeable. If it is the tablets you are shopping for, we compare the options in our guide to where to buy oral semaglutide.

Two practical points the price tags do not tell you. Oral semaglutide has a fussy administration rule: the FDA label says take it on an empty stomach in the morning with no more than four ounces of water, swallow whole, and wait at least 30 minutes before food, other drinks or any other oral medication. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist rather than a peptide, so it has no such restriction — take it with or without food — but its titration is slow, with a minimum of 30 days at each step and five steps to the top dose.

Both labels say the same thing about stacking: concomitant use with another GLP-1 receptor agonist is not recommended.

What Happened in 2025–2026

A condensed timeline of the Hims GLP-1 saga:

Translation: the $99 (and briefly, $49) compounded semaglutide era at Hims is over. The platform now sells the same FDA-approved drugs anyone else can buy, with a telehealth wrapper and a membership fee attached.

One correction worth making, because it is repeated everywhere: March 9 was not a settlement announcement. Hims' own 10-Q describes it as Novo Nordisk voluntarily dismissing its claims without prejudice, with the right to refile preserved. The dispute was parked, not resolved.

What the $149/Month Membership Includes

• Asynchronous messaging with licensed clinicians, described by Hims as 24/7 unlimited provider messaging
• Eligibility evaluation for weight-loss prescription by a state-licensed provider
• Dose adjustments requested in-app, and side-effect management
• Monthly follow-ups with the assigned care team
• A smart scale at no extra cost (Hims values it at $55; opt-in, ships separately) and in-app weight tracking
• A private members-only community group
• Partner discounts on things like meal kits and fitness apps
• Optional add-ons: nausea support, B-vitamin shots, behavioral coaching

What it does not include:

• The medication. Every price on the storefront is billed separately, on top of the $149
• Insurance billing. Hims' FAQ says insurance "isn't required, so there are no complicated insurance questions" — there is no benefit check, no prior authorization support, no copay-card workflow
• FSA/HSA eligibility on the membership fee. The medication fee is eligible; the membership fee is not
• Baseline labs ordered before prescribing — labs appear nowhere in Hims' weight-loss FAQs or product pages
• Obesity medicine specialists — clinicians are general telehealth providers
• 24/7 phone access for emergencies

On visits: Hims says treatment may be determined without a video visit depending on your state, and schedules a video or audio appointment only where one is needed. The default is still asynchronous.

That labs point matters. Many physicians consider lab work before starting GLP-1 standard of care, especially for patients with diabetes, kidney disease, or thyroid concerns.

Real Cost Scenarios

Every Hims number is medication plus the mandatory membership. Month one is cheaper only because the membership is discounted to $39.

Year 1 assumes one discounted month plus eleven at the full rate, at a stable dose. Hims notes that pricing may vary by dosage, so a titration up the label can move your number.

So the honest range is $3,466 to $24,466 in year one, and the number that decides it is which presentation you are prescribed, not which molecule. For the other ways to fill the same molecule and what each one runs, see our guide to where to buy semaglutide.

Branded vs Compounded: What the Shift Did to Hims' Profitability

This is the question investors keep typing into search, and the company's own filings answer it more clearly than any analyst note.

Compounded semaglutide was a high-margin product Hims made money on twice — the pharmacy fill and the subscription. Reselling branded Wegovy and Zepbound is a distribution business at someone else's list price. The Q2 2026 numbers show exactly that trade:

Revenue grew 38% year over year while gross margin fell 12 points. Hims' 10-Q states that gross margin "is expected to remain below comparative periods in the near term, primarily as a result of the 2026 US WL Announcement and recent international acquisitions," and warns that "our margins may be impacted by the cost of procuring branded medications and limitations on our ability to pass through price increases." The first half of 2026 also carried $28.5 million of non-recurring inventory write-downs inside cost of revenue tied to the shift, and $38.1 million of restructuring and related charges overall. The Q2 net loss is not all GLP-1 — it also absorbs $47.5 million of legal contingencies and $28.8 million of acquisition costs — but the margin compression is attributed directly to the weight-loss change.

Two things follow for patients. First, the $149 membership is not an add-on that Hims might drop; it is what replaces the compounding margin, which is why medication cannot be bought without it. Second, Hims has limited room to discount branded drugs further, because it does not set their price. If you are hunting for a cheaper number, the lever is which product you are prescribed, not which telehealth logo is on the box.

Worth noting for context: Hims told investors that a majority of its total US revenue in the first half of 2026 came from non-GLP-1 offerings. Weight loss is the loud part of this company, not the largest part.

Where Hims Sits vs Competitors

Hims figures were checked against hims.com on August 20, 2026. Competitor figures come from our earlier review of each platform and move quarterly. One current difference is worth flagging because it changes the maths for insured patients: Ro's weight-loss page lists its GLP-1s as "insurance or cash-pay" and describes an insurance concierge that files prior authorization paperwork on your behalf, and it now carries orforglipron alongside Wegovy and Zepbound. Hims runs cash-pay only.

Strengths

• Smooth digital experience — onboarding, refills, messaging are polished
• Authorized provider for branded GLP-1s — accessible without changing primary care
• Ten branded GLP-1s in one storefront — injectables and four tablets, including drugs most telehealth platforms do not carry yet
• Flat, published cash pricing — no benefit investigation, no surprise pharmacy quote, and the medication fee is FSA/HSA eligible
• Branded medication — same drug as the pharmacy, full label and traceability
• Side-effect management in-app — nausea support, dose pauses, in-app dose-change requests

Weaknesses

• $149/month membership on top of medication, and it is mandatory — you cannot buy the drug without it
• No more compounded option on the storefront — the cheap entry point is gone
• No insurance route at all — if your plan covers Wegovy or Zepbound, Hims is the wrong door
• Self-pay is expensive vs other telehealth options once the membership is counted
• Cancelling the membership cancels the medication plan — the two are tied in one direction
• The $1,899 tier — the same tirzepatide is $299 as a vial or KwikPen and $1,899 as standard branded pens
• Asynchronous by default — video or audio only where a state requires it, which is harder for complex situations
• No baseline labs — below standard practice for chronic prescriptions
• No obesity medicine specialists — clinicians are generalists
• Not available in all 50 states — eligibility varies by jurisdiction
• Auto-renew membership — easy to forget about; harder to cancel than expected

Who Hims Works Well For

• Adults who want fast online onboarding to a branded GLP-1
• Cash payers with no weight-loss coverage, who would otherwise face retail pharmacy pricing
• People who want an oral GLP-1 and cannot find a prescriber carrying Foundayo or the Wegovy pill
• People who dislike going to a clinic and would otherwise not start treatment
• Tech-comfortable users who prefer in-app messaging over phone calls

Who Should Look Elsewhere

• Patients with complex medical history needing a specialist
• Anyone whose insurance covers a GLP-1 — Hims cannot bill it, so you would pay cash on top of premiums you are already paying
• People on Medicare or Medicaid for whom the membership is unnecessary
• Patients seeking the cheapest possible compounded option — Henry Meds and Mochi are now cheaper for compounded
• Anyone whose primary care doctor will prescribe and bill insurance directly
• Patients with kidney disease, prior pancreatitis, or thyroid history who want pre-screening labs

How To Cancel If You Want To

Hims memberships auto-renew. To cancel:

1. Log in to the Hims account dashboard
2. Go to Account → Subscription
3. Click Manage Subscription
4. Select Cancel

Two things to know before you click. Cancelling the membership also cancels any active medication plan and your access to care through the platform — Hims states this explicitly. Cancelling only the medication plan does not cancel the membership, so you keep paying $149/month unless you cancel that separately.

Cancellation is typically effective at the end of the current billing period. Confirmation email arrives within hours. If you don't see it: contact support — some users report needing to follow up explicitly.

What People Get Wrong About Hims GLP-1

• "Hims is still the cheapest GLP-1 option." Not since the shift to branded. Henry Meds and Mochi are cheaper for compounded; anyone with commercial coverage will beat every Hims price by using it.
• "It's just like buying from a pharmacy." It is — with a mandatory $149/month membership, and no insurance accepted.
• "The advertised price is what I pay." Every headline price is medication only. Add $149.
• "The compounded version is still available." Not on the storefront. Hims' own filing describes compounded access as limited-scale only.
• "They settled with Novo Nordisk, so it's over." Novo dismissed its claims without prejudice and kept the right to refile.
• "Hims and Zepbound means one price." Zepbound is listed twice, at $299 and at $1,899, depending on the presentation.
• "All Hims products are interchangeable with brand-name drugs." The branded products are the same as anywhere else; what differs is the channel and pricing.
• "They check my labs first." No lab requirement appears anywhere in the weight-loss materials.

Frequently Asked Questions

Does Hims still sell compounded semaglutide? Not on the public storefront — every one of the ten weight-loss products listed in August 2026 is a branded, FDA-approved medication. Hims' Q2 2026 quarterly report says it still provides access to compounded GLP-1 medications through the platform "on a limited scale," and that it uses only 503A compounding pharmacies for those fills.

How much is Hims GLP-1 per month? Medication runs $149/month (Wegovy Pill, Ozempic Pill, Foundayo Pill), $199/month (Wegovy Pen, Ozempic injection), $299/month (Zepbound Vial or KwikPen) or $1,899/month (standard branded Zepbound and Mounjaro pens). Add the mandatory membership — $39 for month one, then $149/month — for an all-in figure of $188 in month one and $298 to $2,048 a month after that.

How much does Hims cost in total for weight loss? The cheapest realistic path is $188 in month one and $298/month afterwards, which is $3,466 for year one on a $149 pill. A Zepbound vial or KwikPen works out to $5,266 for year one. The standard branded Zepbound or Mounjaro pens run $24,466. Those figures assume a stable dose; Hims notes pricing can vary by dosage.

What GLP-1 pill does Hims sell? Four tablets. The Wegovy Pill (oral semaglutide, FDA-approved for weight management, maintenance dose 25 mg daily) and a Wegovy Pill Microdosing Plan, both from $149/month. The Ozempic Pill (oral semaglutide on the diabetes label, so off-label for weight loss) from $149/month. And Foundayo, Eli Lilly's orforglipron tablet approved for chronic weight management, from $149/month — a once-daily pill titrated from 0.8 mg up to a maximum of 17.2 mg, taken with or without food.

Is Hims a real prescription? Yes. Hims connects users with state-licensed clinicians who write real prescriptions for FDA-approved GLP-1 medications.

Does Hims order labs before prescribing GLP-1? No lab requirement appears anywhere in Hims' weight-loss FAQs or product pages, and none is needed to start. Many physicians consider baseline labs standard care for a chronic prescription.

Is Hims available in all 50 states? No. Hims says GLP-1s "are not yet available in all 50 states"; availability varies by jurisdiction.

Does insurance work with Hims? No. Hims' own FAQ says insurance "isn't required, so there are no complicated insurance questions or health insurance plan considerations," and every GLP-1 is listed at a flat cash price with no benefit check or prior-authorization support. The medication fee is FSA/HSA eligible; the membership fee is not.

Do I have to do a video visit with Hims? Usually not. Hims says treatment may be determined without a video visit depending on your state, and only schedules a video or audio appointment where one is required. Follow-ups run through in-app messaging.

Can I buy Hims GLP-1 medication without the membership? No. Hims states that medication is not available without an active membership, and that cancelling the membership cancels any active medication plan along with platform access.

Did moving from compounded to branded GLP-1s hurt Hims' profitability? Yes, on the margin line. Hims' gross margin fell to 64% in Q2 2026 from 76% a year earlier, adjusted EBITDA margin halved from 15% to 8%, and the company posted an $86.3 million net loss against a $42.5 million profit in Q2 2025 — all while revenue grew 38% to $753.2 million. The 10-Q attributes the margin decline partly to the 2026 US weight-loss shift and warns that margins may keep being squeezed by "the cost of procuring branded medications and limitations on our ability to pass through price increases." Reselling someone else's branded drug is structurally lower-margin than compounding your own.

How does Hims compare to Ro for GLP-1? Both moved to branded GLP-1s in 2026. The live difference is payment: Ro lists its GLP-1s as insurance or cash-pay and runs an insurance concierge that files prior authorizations, while Hims is cash-only behind a mandatory membership. Both now carry orforglipron.

What happened with the $49 pill announcement? Hims announced $49 compounded semaglutide on February 5, 2026. Novo Nordisk sued for patent infringement on February 9 and asked for an injunction lasting until its semaglutide patent expires on December 5, 2031. Novo voluntarily dismissed the case without prejudice on March 9, 2026, and Hims moved its US weight-loss offering to branded medication.

Last reviewed: August 20, 2026

Sources

• Hims GLP-1 2026: Complete Guide — Telehealth Ally
• Hims GLP-1 Weight Loss: $49 Pill, Novo Nordisk Response — Yahoo Finance
• Hims & Hers GLP-1 Reviews: Pricing — Mira Health
• Weight Loss — Hims (product lineup and prices, checked August 20, 2026)
• Weight Loss FAQs — Hims (membership terms, insurance, video visits)
• Hims & Hers Health, Inc. Form 10-Q for the quarter ended June 30, 2026 — U.S. Securities and Exchange Commission
• FOUNDAYO (orforglipron) tablet — prescribing information, DailyMed
• WEGOVY (semaglutide) injection and tablet — prescribing information, DailyMed

References

• FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food & Drug Administration
• Glucagon-Like Peptide-1 Receptor Agonists — StatPearls, NCBI Bookshelf